Accreditation/Credit Designation

This is not a CME-certified (accredited) activity.

Acknowledgement of Commercial Support

This activity is supported by educational grant from Daiichi Sankyo, Inc.

Slide Presentations for: Medical Crossfire®: Exploring HER2 Targeted Treatment Approaches for Gastrointestinal Cancers

Click here to download the full slide deck from this year's meeting!

Friday, January 24, 2020

Dinner and Registration: 6:00 PM – 7:00 PM
Scientific Session: 7:00 PM – 9:00 PM

Location:
The Park Central San Francisco
Dinner and Program: Metropolitan Ballroom 3 - 2nd Floor
50 3rd Street,
San Francisco, CA
(415) 974-6400

HER2-Targeted Treatment Approaches for Gastrointestinal (GI) Cancers Overview

In recent years, HER2 expression has been increasingly recognized as a frequent abnormality in gastric and gastroesophageal cancers, enabling oncologists to administer HER2-targeted therapies to their patients. HER2 amplification and overexpression, however, are much more heterogeneous in these tumor types compared to breast cancer, with incomplete membrane staining resulting in the need for an exclusive scoring and interpretation system for GI tumor samples. Moreover, novel anti-HER2 agents, including biosimilars and antibody-drug conjugates, have emerged to combat tumor resistance and overcome intratumoral heterogeneity in GI cancers.

Medical Crossfire®: Exploring HER2-Targeted Treatment Approaches for Gastric and Other GI Cancers is a CME-certified dinner symposium ancillary to the 2020 Gastrointestinal Cancers Symposium (ASCO GI) being held in San Francisco, CA. This live educational activity will help physicians assess the latest available data on HER2-targeted treatment strategies for the care of patients with GI cancers. Renowned experts will discuss the role of HER2 expression in gastric and gastroesophageal cancers and how it compares to what has been learned from the treatment of breast cancer. They will also share best practices for incorporating key data from landmark clinical trials of HER2-positive GI cancers into the everyday clinic, as well as review emerging novel anti-HER2 agents under investigation. Using challenging patient case scenarios in the Medical Crossfire® format, the panelists will provide evidence-based recommendations for managing patients with HER2-positive GI cancers from diagnosis through treatment, as well as debate the best strategies for combining multiple targeted therapies. In this time of continued knowledge expansion of the biologic drivers underlying GI cancers, we look forward to you joining us to learn how to bring the latest HER2-targeted treatment strategies to your patients with GI cancers.

Benefits of Attending This Symposium on the Use of HER2-Targeted Therapies in GI Cancers, Hosted by PER®

  • Gain awareness of the clinical trials evaluating current and emerging HER2-targeted therapies for GI cancer treatment that may affect your practice in the future
  • Understand challenges in HER2 testing for GI cancers compared to other tumor types
  • Learn how the experts and your peers are managing challenging HER2-positive gastric and gastroesophageal cancer cases
  • Ask the experts about best practices for mitigating adverse events related to HER2-targeted therapies for gastric and gastroesophageal cancer treatment

Acknowledgement of Commercial Support

This activity is supported by educational grant from Daiichi Sankyo, Inc.

Target Audience: HCPs Who Treat Gastric and Other GI Cancers

This educational program is directed toward all attendees of the 2020 Gastrointestinal Cancers Symposium, including medical oncologists, surgical oncologists, radiation oncologists, hepatologists, pathologists, and gastroenterologists interested in the treatment of GI cancers. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with GI cancers are invited to participate.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the rationale for the use of HER2-targeted therapies for the treatment of patients with GI malignancies
  • Evaluate molecular testing strategies for the detection of HER2 in GI malignancies
  • Assess data from clinical trials exploring HER2-targeted treatments for patients with GI malignancies
  • Apply HER2-targeted therapies in clinical practice for the treatment of patients with GI malignancies

Program Chair

David H. Ilson
David H. Ilson, MD, PhD
Professor of Medicine
Weill Medical College of Cornell University
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Faculty

Ryan B. Corcoran
Ryan B. Corcoran, MD, PhD
Director, Gastrointestinal Cancer Center Program
Scientific Director, Termeer Center for Targeted Therapy
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine, Harvard Medical School
Boston, MA
 
Aiwu Ruth He
Aiwu Ruth He, MD, PhD
Medical Oncologist
MedStar Georgetown University Hospital
Washington, DC

Click here to download the full slide deck from this year's meeting!


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By